Imrecoxib 艾瑞昔布; BAP-909|cas:395683-14-4|西域试剂

Imrecoxib 艾瑞昔布; BAP-909,99.64%

产品编号：Bellancom-114200| CAS NO：395683-14-4| 分子式：C₂₁H₂₃NO₃S| 分子量：369.48

Imrecoxib（BAP-909）艾瑞昔布是选择性环氧合酶 2 (COX-2) 抑制剂，IC50 值为 18 nM，也可以抑制 COX1 活性，IC50 值为 115 nM。Imrecoxib（BAP-909) 艾瑞昔布具有抗炎作用。

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-114200		￥500.00	杭州北京（现货）
Bellancom-114200		￥800.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Imrecoxib 艾瑞昔布; BAP-909

产品介绍

Imrecoxib（BAP-909）艾瑞昔布是选择性环氧合酶 2 (COX-2) 抑制剂，IC₅₀ 值为 18 nM，也可以抑制 COX1 活性，IC₅₀ 值为 115 nM。Imrecoxib（BAP-909) 艾瑞昔布具有抗炎作用。

生物活性

Imrecoxib (BAP-909) is a novel and selective cyclooxygenase 2 (COX-2) inhibitor with an IC₅₀ value of 18 nM, it also inhibits COX1- activity with an IC₅₀ value of 115 nM. Imrecoxib (BAP-909) has anti-inflammatory effect.

体外研究

Imrecoxib (BAP-909) (0.1-10 µM; 24 hours) decreases COX-2 mRNA level induced by PMA+LPS at a dose dependent manner in U937 cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

RT-PCR

Cell Line:	U937 cells
Concentration:	0.1 µM; 1 µM; 10 µM
Incubation Time:	24 hours
Result:	Decreased COX-2 mRNA level.

体内研究
(In Vivo)

Imrecoxib (BAP-909) (gastrointestinal administration; 5-20 mg/kg; 1 hour before carrageenan injection) inhibits carrageenan-induced acute inflammation, and the inhibitory effect is maximal at 4 hours.
Imrecoxib (BAP-909) (gastrointestinal administration; 5-20 mg/kg; started on day 7; 26 days) diminishes the secondary paw swelling and inhibits heat-inactivated BCG induced-inflammtory polyarthritis.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Rat carrageenan-induced edema model
Dosage:	5 mg/kg, 10 mg/kg, 20 mg/kg
Administration:	Gastrointestinal administration; 5-20 mg/kg; 1 hour before carrageenan injection
Result:	Inhibited the edema response with different doses.

Animal Model:	Rat adjuvant-induced arthritis (AIA) model
Dosage:	5 mg/kg, 10 mg/kg, 20 mg/kg
Administration:	Gastrointestinal administration; 5-20 mg/kg; started on day 7; 26 days
Result:	Inhibited adjuvant-induced chronic inflammation at the doses of 10 and 20 mg/kg.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Rat carrageenan-induced edema model
Dosage:	5 mg/kg, 10 mg/kg, 20 mg/kg
Administration:	Gastrointestinal administration; 5-20 mg/kg; 1 hour before carrageenan injection
Result:	Inhibited the edema response with different doses.

Animal Model:	Rat adjuvant-induced arthritis (AIA) model
Dosage:	5 mg/kg, 10 mg/kg, 20 mg/kg
Administration:	Gastrointestinal administration; 5-20 mg/kg; started on day 7; 26 days
Result:	Inhibited adjuvant-induced chronic inflammation at the doses of 10 and 20 mg/kg.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Rat carrageenan-induced edema model
Dosage:	5 mg/kg, 10 mg/kg, 20 mg/kg
Administration:	Gastrointestinal administration; 5-20 mg/kg; 1 hour before carrageenan injection
Result:	Inhibited the edema response with different doses.

Animal Model:	Rat adjuvant-induced arthritis (AIA) model
Dosage:	5 mg/kg, 10 mg/kg, 20 mg/kg
Administration:	Gastrointestinal administration; 5-20 mg/kg; started on day 7; 26 days
Result:	Inhibited adjuvant-induced chronic inflammation at the doses of 10 and 20 mg/kg.

性状

Solid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (270.65 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.7065 mL	13.5325 mL	27.0651 mL
5 mM	0.5413 mL	2.7065 mL	5.4130 mL
10 mM	0.2707 mL	1.3533 mL	2.7065 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (5.63 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (5.63 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (5.63 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (5.63 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在西域网站选购。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

参考文献

. Chen XH, et al. Imrecoxib: a novel and selective cyclooxygenase 2 inhibitor with anti-inflammatory effect. Acta Pharmacol Sin. 2004 Jul;25(7):927-31. [Content Brief]

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

产品编号(Item Number)

批号(Lot Number)

Imrecoxib 艾瑞昔布; BAP-909,99.64%

Imrecoxib 艾瑞昔布; BAP-909

化学品安全说明书(MSDS)

质检证书(COA)

在线咨询